These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36525477)

  • 1. Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis.
    Verde F; Milone I; Maranzano A; Colombo E; Torre S; Solca F; Doretti A; Gentile F; Manini A; Bonetti R; Peverelli S; Messina S; Maderna L; Morelli C; Poletti B; Ratti A; Silani V; Ticozzi N
    Ann Clin Transl Neurol; 2023 Jan; 10(1):118-129. PubMed ID: 36525477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis.
    Gairing SJ; Danneberg S; Kaps L; Nagel M; Schleicher EM; Quack C; Engel S; Bittner S; Galle PR; Schattenberg JM; Wörns MA; Luessi F; Marquardt JU; Labenz C
    JHEP Rep; 2023 Apr; 5(4):100671. PubMed ID: 36866390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
    Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J
    JAMA Neurol; 2023 Mar; 80(3):287-297. PubMed ID: 36745446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic correlates of serum neurofilament light chain levels in amyotrophic lateral sclerosis.
    Verde F; Milone I; Colombo E; Maranzano A; Solca F; Torre S; Doretti A; Gentile F; Manini A; Bonetti R; Peverelli S; Messina S; Maderna L; Morelli C; Poletti B; Ratti A; Silani V; Ticozzi N
    Front Aging Neurosci; 2023; 15():1132808. PubMed ID: 37009451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
    Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
    J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis.
    Falzone YM; Domi T; Mandelli A; Pozzi L; Schito P; Russo T; Barbieri A; Fazio R; Volontè MA; Magnani G; Del Carro U; Carrera P; Malaspina A; Agosta F; Quattrini A; Furlan R; Filippi M; Riva N
    Eur J Neurol; 2022 Jul; 29(7):1930-1939. PubMed ID: 35263489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylated tau in plasma could be a biomarker of lower motor neuron impairment in amyotrophic lateral sclerosis.
    Verde F; Milone I; Colombo E; Maranzano A; Dubini A; Colombrita C; Gentile F; Doretti A; Torre S; Messina S; Morelli C; Torresani E; Poletti B; Priori A; Maderna L; Ratti A; Silani V; Ticozzi N
    Neurol Sci; 2023 Oct; 44(10):3697-3702. PubMed ID: 37369876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
    Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI
    Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum glial fibrillary acidic protein is sensitive to acute but not chronic tissue damage in cerebral small vessel disease.
    Gattringer T; Enzinger C; Pinter D; Fandler-Höfler S; Kneihsl M; Haidegger M; Eppinger S; Demjaha R; Buchmann A; Jerkovic A; Schmidt R; Khalil M
    J Neurol; 2023 Jan; 270(1):320-327. PubMed ID: 36056929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
    Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K
    J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
    Wessels MH; Van Lierop ZY; Noteboom S; Strijbis EM; Heijst JA; Van Kempen ZL; Moraal B; Barkhof F; Uitdehaag BM; Schoonheim MM; Killestein J; Teunissen CE
    Mult Scler; 2023 Sep; 29(10):1229-1239. PubMed ID: 37530045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4.
    Kessler C; Ruschil C; Abdelhak A; Wilke C; Maleska A; Kuhle J; Krumbholz M; Kowarik MC; Schüle R
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between cerebrospinal fluid/serum albumin quotient and phenotype in amyotrophic lateral sclerosis: a retrospective study on 328 patients.
    Verde F; Ferrari I; Maranzano A; Ciusani E; Torre S; Milone I; Colombo E; Doretti A; Peverelli S; Ratti A; Maderna L; Poletti B; Messina S; Morelli C; Silani V; Ticozzi N
    Neurol Sci; 2023 May; 44(5):1679-1685. PubMed ID: 36646859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
    Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
    Front Immunol; 2021; 12():647618. PubMed ID: 33796113
    [No Abstract]   [Full Text] [Related]  

  • 15. Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
    Lin TY; Schindler P; Grittner U; Oertel FC; Lu A; Motamedi S; Yadav SK; Duchow AS; Jarius S; Kuhle J; Benkert P; Brandt AU; Bellmann-Strobl J; Schmitz-Hübsch T; Paul F; Ruprecht K; Zimmermann HG
    Mult Scler Relat Disord; 2022 Nov; 67():104100. PubMed ID: 36049341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder: Longitudinal Analysis of Serum Glial Fibrillary Acidic Protein.
    Hyun JW; Kim Y; Kim SY; Lee MY; Kim SH; Kim HJ
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33846219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyotrophic lateral sclerosis phenotypes significantly differ in terms of magnetic susceptibility properties of the precentral cortex.
    Conte G; Contarino VE; Casale S; Morelli C; Sbaraini S; Scola E; Trogu F; Siggillino S; Cinnante CM; Caschera L; Lo Russo FM; Triulzi FM; Silani V
    Eur Radiol; 2021 Jul; 31(7):5272-5280. PubMed ID: 33399906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation.
    Jiang X; Shen C; Teunissen CE; Wessels M; Zetterberg H; Giovannoni G; Singh CM; Caba B; Elliott C; Fisher E; de Moor C; Belachew S; Gafson AR
    Mult Scler; 2023 Aug; 29(9):1070-1079. PubMed ID: 37317870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.
    Barro C; Healy BC; Liu Y; Saxena S; Paul A; Polgar-Turcsanyi M; Guttmann CRG; Bakshi R; Kropshofer H; Weiner HL; Chitnis T
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36376097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Benninger F; Glat MJ; Offen D; Steiner I
    J Clin Neurosci; 2016 Apr; 26():75-8. PubMed ID: 26602604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.